MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera

NCT ID: NCT05269771

Last Updated: 2025-11-05

Basic Information

• Recruitment Status: NO_LONGER_AVAILABLE
• Study Classification: EXPANDED_ACCESS

Brief Summary

The purpose of this Cohort Treatment Plan is to allow access to ruxolitinib for eligible patients diagnosed with Polycythemia Vera. The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.

Detailed Description

The requesting Treating Physician must submit a request for access to drug (often referred to as Compassionate Use) to Novartis which will review and approve by the medical team experienced with the drug and indication.

Conditions

Polycythemia Vera

Interventions

Ruxolitinib

Patients may self-administer daily ruxolitinib tablets qd or bid orally, without regard to food, in accordance with specified dosing schedule provided by the investigator.

Intervention Type: DRUG

Other Intervention Names

Jakavi

Eligibility Criteria

Inclusion Criteria

Patients eligible for inclusion in this Treatment Plan have to meet all of the following criteria:

1. Male or female aged 12 or over

2. Confirmed diagnosis of PV based on World Health Organization (WHO) criteria

3. Patients must have a treatment history for PV that meets the definition of resistance or intolerance to hydroxyurea (HU) or other cytoreductive therapy

4. Patients with a peripheral blood blast count of 0% at screening

5. Patients must have recovered or stabilized sufficiently from adverse drug reactions associated with prior treatments before beginning treatment with ruxolitinib

6. Patients with an Eastern Cooperative Oncology Group (ECOG) score of 0, 1 or 2 Written patient informed consent must be obtained prior to start of treatment.

Exclusion Criteria

Patients eligible for this Treatment Plan must not meet any of the following criteria:

1. History of hypersensitivity to any drugs or metabolites of similar chemical classes as ruxolitinib.

2. Presence of an active uncontrolled infection including significant bacterial, fungal, viral (including CMV, EBV, HHV-6, HBV, HCV, BK or HIV) or parasitic infection requiring treatment. Infections are considered controlled if appropriate therapy has been instituted and, at the time of screening, no signs of progression are present. Progression of infection is defined as hemodynamic instability attributable to sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection. Patients with inactive chronic infection (without viral replication) can be enrolled.

3. History of progressive multifocal leuko-encephalopathy (PML).

4. Presence of severely impaired renal function defined by serum creatinine > 2 mg/dL (>176.8 μmol/L), or have estimated creatinine clearance < 30 ml/min measured or calculated by Cockroft Gault equation.

5. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, UNLESS they are

• women whose sexual orientation precludes intercourse with a male partner.
• women whose partners have been sterilized by vasectomy or other means.
• using a highly effective method of birth control (i.e. one that results in a less than 1% per year failure rate when used consistently and correctly, such as implants, injectables, combined oral contraceptives, and some intrauterine devices (IUDs); periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) is not acceptable throughout the period of treatment and 30 days after treatment discontinuation.

Any female aged 8 years and above is to be treated as a woman of child-bearing potential.

Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL [for US only: and estradiol < 20 pg/mL] or have had surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.

6. Pregnancy

7. Not able to understand and to comply with treatment instructions and requirements

• Minimum Eligible Age: 12 Years
• Maximum Eligible Age: 99 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Novartis Investigative Site

Orange, New South Wales, Australia

Novartis Investigative Site

Leuven, , Belgium

Novartis Investigative Site

Calgary, Alberta, Canada

Novartis Investigative Site

Tehran, , Iran

Novartis Investigative Site

Kfar Saba, Israel, Israel

Novartis Investigative Site

Kfar Saba, , Israel

Novartis Investigative Site

Rehovot, , Israel

Novartis Investigative Site

Tel Aviv, , Israel

Novartis Investigative Site

Tel Giborim Holon, , Israel

Novartis Investigative Site

Groningen, , Netherlands

Novartis Investigative Site

Gdansk, , Poland

Novartis Investigative Site

Katowice, , Poland

Novartis Investigative Site

Krakow, , Poland

Novartis Investigative Site

Warsaw, , Poland

Novartis Investigative Site

Warsaw, , Poland

Novartis Investigative Site

Wałbrzych, , Poland

Novartis Investigative Site

Wroclaw, , Poland

Novartis Investigative Site

Hereford, , United Kingdom

Novartis Investigative Site

Kent, , United Kingdom

Novartis Investigative Site

London, , United Kingdom

Novartis Investigative Site

London, , United Kingdom

Novartis Investigative Site

London, , United Kingdom

Novartis Investigative Site

Oxford, , United Kingdom

Novartis Investigative Site

Poole, , United Kingdom

Novartis Investigative Site

Salisbury, , United Kingdom

Countries

Australia; Belgium; Canada; Iran; Israel; Netherlands; Poland; United Kingdom

Other Identifiers

CINC424B2002I

Identifier Type: -

Identifier Source: org_study_id